According to FutureWise analysis the market for protein a resins in 2023 is US$ 1.32 billion, and is expected to reach US$ 2.83 billion by 2031 at a CAGR of 10%.
The protein A resins have evolved over the years which has resulted in the high affinity of these resins into immunoglobulins. These proteins further bind to the Fc-region of mAbs and Fc-fusion proteins. Rising research activities on monoclonal antibodies, increase in the number of monoclonal antibodies in the pipeline, key players providing novel protein A resin products like next-generation protein A resin for performing clinical trials are some of the key factors responsible for the protein A resins market growth. Conversely, the availability of other purification methods like crystallization, ultrafiltration, capillary electrophoresis and high-pressure folding shall restrain the market growth. Furthermore, the increased necessity for early disease diagnosis along with rising insistence for drugs with lesser side effects shall pave way for growth opportunities during the forecasted timeframe. Moreover, an increased prevalence of appalling diseases like cancer has propelled the investments in research and development activities for developing effective drugs, resulting in the increased protein A resins market demand.